4.48 USD
↗ 0.16 (3.59%)AT CLOSE (11:59 AM EDT)
Genprex, Inc. Common Stock
GNPXNASDAQ • USD
4.90
↗ 0.43 (9.50%)
POST MARKET (AS OF 07:29 PM EDT)
Post Market
AS OF 07:29 PM EDT
4.90
↗ 0.43 (9.50%)
Market: OPEN
GNPX is currently priced at $4.90. Technical and fundamental signals converge bearish — technicals rate "Sell" while fundamentals read "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest GNPX is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Aug 17, 2026.
Open?$4.20
High?$4.89
Low?$4.06
Prev. Close?$4.32
Volume?437.3K
Avg. Volume?229.8K
VWAP?$4.53
Rel. Volume?1.90x
Bid / Ask
Bid?$3.73 × 100
Ask?$5.32 × 100
Spread?$1.59
Midpoint?$4.53
Valuation & Ratios
Market Cap?2.2M
Shares Out?504.9K
Float?10.6M
Float %?99.8%
P/E Ratio?N/A
P/B Ratio?0.13
EPS?-$33.13
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
Themes
Address
3300 BEE CAVE ROAD SUITE 650-227
AUSTIN, TX 78746
Phone: 512-537-7997
AUSTIN, TX 78746
Phone: 512-537-7997
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?77
Short Sent.?80
Piotroski F-Score?0/9Weak
Altman Z-Score?-13.41Distress
Confidence?43%Low
Short InterestLow
Short % of Float?0.35%Low
Short Interest?36.9K
Days to Cover?1.0
Free Float10.6M
Avg Daily Volume50.1K
Settlement Date2026-07-31
Financial Health
Current Ratio?5.61Strong
Quick Ratio?5.61Strong
Cash Ratio?5.38Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?0.13CHEAP▾
Peers100
S&P97
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?1.0CHEAP▾
Peers100
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-98.8%WEAK▾
S&P3
ROA?-82.4%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-14288241
Enterprise Value?$-15867931
Fundamentals ratios updated end of day